NeoCircle: pre- and post-operative ctDNA predicts survival in neoadjuvant-treated breast cancer

ABSTRACT: Persistent circulating tumor DNA (ctDNA) during neoadjuvant treatment (NAT) of early breast cancer (EBC) indicates high-risk disease. Similarly, detection of ctDNA post-resection indicates molecular residual disease (MRD) and impending relapse. For ctDNA to be integrated into EBC management, accessible and scalable diagnostics are required. Here we apply an ultrasensitive, personalized tumor-informed approach to ctDNA evaluation predicated on analyses of structural variants (SVs) using a novel digital PCR (dPCR) SV technology. 136 patients eligible for NAT (29.4% TNBC, 44.9% HR+/HER2− and 24.3% HER2+), enrolled between December 2014 and March 2019, were analyzed from the prospective SCAN-B study (NCT02306096, substudy NeoCircle). ctDNA detection at baseline was 89.7%; end-NAT ctDNA-positiv

SUBMITTER: Anthony George 

PROVIDER: S-SCDT-10_1038-S44321-026-00447-Z | biostudies-other |

REPOSITORIES: biostudies-other